导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 21.90% | 338/4773 |
| 近一周 | 0.21% | 715/5465 |
| 近一月 | -7.04% | 4420/5421 |
| 近一季 | -21.04% | 4987/5231 |
| 近半年 | 18.91% | 243/4920 |
| 近一年 | 28.70% | 258/4394 |
| 近两年 | 117.46% | 450/2954 |
| 近三年 | 77.30% | 275/2253 |
| 成立以来 | 126.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.76% 2470/4961 |
71.14% 261/5312 |
- - |
- - |
| 2025 | 41.18% 745/4813 |
-2.51% 2900/3635 |
2.73% 1395/4076 |
34.24% 1017/4524 |
5.01% 465/4813 |
| 2024 | 7.75% 1623/3463 |
-1.01% 1165/2808 |
-2.83% 1259/3014 |
16.94% 1302/3129 |
-4.21% 2450/3463 |
| 2023 | -25.65% 1978/2656 |
-0.62% 1809/2280 |
-4.48% 1188/2385 |
-17.25% 2272/2515 |
-5.35% 1328/2655 |
| 2022 | -29.06% 1586/2207 |
-19.32% 1445/1919 |
7.90% 415/2016 |
-16.84% 1509/2113 |
-2.02% 1771/2208 |
| 2021 | 21.23% 165/1822 |
-6.69% 1029/1255 |
36.90% 25/1330 |
-7.08% 1020/1466 |
2.13% 692/1822 |
| 2020 | 97.21% 15/1250 |
6.43% 41/1028 |
37.36% 12/1067 |
6.80% 815/1164 |
26.31% 23/1184 |
| 2019 | - - |
- - |
- - |
8.46% 64/850 |
8.17% 344/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏创成长ETF VS. 长安沪深300非周期A(740101) |